Form IRANNOTICE TAKEDA PHARMACEUTICAL
Tweet
Share
E-mailU.S. Securities and Exchange
Commission
100 F Street, N.E.
Washington, DC 20549
June 17, 2026
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Dear Sirs:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Takeda Pharmaceutical Company Limited has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended March 31, 2026, which was filed with the Securities and Exchange Commission on June 17, 2026.
Sincerely,
| /s/ Milano Furuta | ||||||||||||||
| Milano Furuta | ||||||||||||||
Director and Chief Financial Officer | ||||||||||||||
Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668, Japan | ||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY7,000 at Nomura/Instinet
- Best Crypto to Buy Now: Why Remittix Could Outrun Solana and XRP in the Next Market Surge
- Stay Prepared for Canada's Grid Outages with Up to 65% Off Jackery Power Stations During Prime Big Deal Days' Early Access Event
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
